Teva Pharmaceutical Industries Limited (NYSE:TEVA) Holdings Raised by Jones Financial Companies Lllp

Jones Financial Companies Lllp lifted its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 145.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,592 shares of the company’s stock after purchasing an additional 5,091 shares during the quarter. Jones Financial Companies Lllp’s holdings in Teva Pharmaceutical Industries were worth $189,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. FMR LLC raised its stake in shares of Teva Pharmaceutical Industries by 49.5% during the third quarter. FMR LLC now owns 62,740,763 shares of the company’s stock valued at $1,130,589,000 after purchasing an additional 20,762,226 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd grew its holdings in Teva Pharmaceutical Industries by 6.8% during the third quarter. Clal Insurance Enterprises Holdings Ltd now owns 34,543,812 shares of the company’s stock worth $621,337,000 after acquiring an additional 2,204,623 shares during the period. Lingotto Investment Management LLP grew its holdings in Teva Pharmaceutical Industries by 2.6% during the fourth quarter. Lingotto Investment Management LLP now owns 27,192,388 shares of the company’s stock worth $599,320,000 after acquiring an additional 688,862 shares during the period. Migdal Insurance & Financial Holdings Ltd. grew its holdings in Teva Pharmaceutical Industries by 2.2% during the fourth quarter. Migdal Insurance & Financial Holdings Ltd. now owns 26,035,422 shares of the company’s stock worth $573,822,000 after acquiring an additional 569,412 shares during the period. Finally, State Street Corp grew its holdings in Teva Pharmaceutical Industries by 10.0% during the third quarter. State Street Corp now owns 19,500,683 shares of the company’s stock worth $351,402,000 after acquiring an additional 1,778,268 shares during the period. 54.05% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on TEVA shares. UBS Group lowered their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a report on Thursday, January 30th. Bank of America dropped their price target on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating on the stock in a research note on Thursday, March 6th. StockNews.com cut Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research note on Friday, March 7th. Barclays dropped their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Thursday, January 30th. Finally, Piper Sandler lifted their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research note on Friday, January 17th. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $23.43.

Teva Pharmaceutical Industries Trading Up 0.1 %

NYSE:TEVA opened at $16.50 on Friday. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. Teva Pharmaceutical Industries Limited has a fifty-two week low of $12.51 and a fifty-two week high of $22.80. The stock’s 50-day moving average is $18.38 and its two-hundred day moving average is $18.31. The stock has a market cap of $18.70 billion, a PE ratio of -11.38, a price-to-earnings-growth ratio of 1.44 and a beta of 0.82.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. As a group, equities research analysts forecast that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Roberto Mignone sold 286,000 shares of Teva Pharmaceutical Industries stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the completion of the sale, the director now directly owns 695,000 shares in the company, valued at $15,296,950. The trade was a 29.15 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.55% of the stock is owned by corporate insiders.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.